New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
UP AFTER EARNINGS: Microsoft (MSFT), up 3.5%... Starbucks (SBUX), up 1.2%... Juniper (JNPR), up 5.4%... Kimberly Clark (KMB), up 2%... Stanley Black & Decker (SWK), up 1%. ALSO HIGHER: BioDelivery (BDSI), up 43% after announcing positive top-line results from BEMA Phase III trial with Endo (ENDP) unit... Adamis (ADMP), up 6% after receiving Notice of Allowance of patent claims for immunotherapy portfolio. DOWN AFTER EARNINGS: International Game (IGT), down 11%... Intuitive Surgical (ISRG), down 5.5%... Xerox (XRX), down 2.6%... W.W. Grainger (GWW). down 4.5%... Kansas City Southern (KSU), down 8%. ALSO LOWER: PTC Therapeutics (PTCT), down 18% after announcing EMA adopted negative opinion on MAA for Atuluren approval... FireEye (FEYE), down 2.4% following downgrade at Barclays.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
November 17, 2015
07:56 EDTFEYE, MSFTUBS to hold a conference
Global Technology Conference is being held in San Francisco on November 16-18 with webcasted company presentations to begin on November 17 at 10:45 am.; not all company presentations may be webcasted. Webcast Link
07:52 EDTSBUXMorgan Stanley to hold a conference
Subscribe for More Information
06:59 EDTGWWGrainger downgraded to Underweight from Neutral at Atlantic Equities
Subscribe for More Information
06:16 EDTMSFTMicrosoft turns around flawed security technology, NY Times says
Subscribe for More Information
November 16, 2015
17:02 EDTSBUX, MSFTPoint72 added to lululemon position, subtracted from Netflix position
Subscribe for More Information
16:00 EDTMSFTOptions Update; November 16, 2015
Subscribe for More Information
09:06 EDTENDPDiplomat seen as compelling amid specialty pharmacy fallout
Shares of specialty pharmacy operator Diplomat Pharmacy (DPLO) and pharmacy benefit manager Express Scripts (ESRX) have each been knocked down by the negative news surrounding the sector amid the troubles faced by Valeant (VRX) and others, but an analyst at Leerink contends in a note to investors that the pullbacks in both stocks provide buying opportunities. BACKGROUND: Drugmaker Valeant and its prior specialty pharmacy partner, Philidor Rx Services, have been at the center of the firestorm engulfing the sector. Following claims that Philidor urged its employees to modify prescriptions to ensure more orders of Valeant-branded drugs rather than generics, as well as other allegations of wrongdoing, Express Scripts (ESRX) and peer CVS Health (CVS) terminated Philidor from their networks. The day after those termination announcements, Valeant said that it was severing all ties with Philidor and that the pharmacy planned to shut down operations as soon as possible, consistent with applicable laws. Valeant has subsequently said that Philidor has committed to cease operations by January 30, 2016, at the latest. More recently, Express Scripts, the nation's largest pharmacy benefit manager, announced that it stopped doing business with Linden Care, accusing it of being a "captive" pharmacy that dispenses mostly products made by Horizon Pharma (HZNP). In turn, Horizon called the idea that Linden Care is a captive pharmacy "entirely false," stating that "at best Express Scripts is being reckless in its allegations and at worse it is intentionally attempting to mislead investors." Express Scripts' move also impacted shares of Insys Therapeutics (INSY), which reportedly also used Linden Care to fulfill prescription for its drugs. DIPLOMAT LIKELY TO STAY IN-NETWORK: Leerink analyst David Larsen acknowledged that recent events indicate that Express Scripts appears to be evaluating certain retail pharmacies and their relationships with manufacturers, but he believes Diplomat's mix of drugs for diseases like multiple sclerosis, HIV, hepatitis C and cancer differentiate it as a "true" specialty pharmacy. Larsen does not think Diplomat is at risk of being excluded from the pharmacy networks of Express Scripts, CVS or UnitedHealth's (UNH) Optum, he tells investors. Larsen expects limited distribution agreements to stay an important channel strategy for drugmakers and believes these agreements are appropriate for high cost specialty drugs that require special handling and additional services to manage patient adherence. The analyst, who thinks Diplomat remains well positioned to deliver annual growth of over 30% in the next several years, keeps an Outperform rating on its shares. EXPRESS BUYING OPPORTUNITY: Larsen also thinks concerns around manufacturer and pharmacy relationships have put unwarranted pressure on shares of Express Scripts. He does not expect Express Scripts to disclose new lawsuits around rebate dollars owed over other manufacturer disputes and keeps an Outperform rating on the stock, which he views as having an "attractive" valuation. WHAT'S NOTABLE: Larsen also thinks that the specialty channel remains an opportunity for Walgreens Boots Alliance (WBA) and believes its proposed acquisition of Rite Aid (RAD) can strengthen its specialty offering. The analyst keeps an Outperform rating on Walgreens shares as well. PRICE ACTION: Over the last three months, Diplomat Pharmacy shares have declined 28%, Express Scripts has fallen 6% and Walgreens has dropped 14%.
07:18 EDTIGTDeutsche Bank to hold a conference
Subscribe for More Information
07:16 EDTENDPHayman Capital gives quarterly update on stakes
NEW STAKES: Impax (IPXL), CF Industries (CF), GW Pharmaceuticals (GWPH), ProNAi Therapeutics (DNAI). INCREASED STAKES: BioMarin (BMRN), NMI Holdings (NMIH), Vertex (VRTX), Endo (ENDP). DECREASED STAKES: Mylan (MYL). LIQUIDATED STAKES: Perrigo (PRGO), Oasis Petroleum (OAS), Whiting Petroleum (WLL), Newfield Exploration (NFX), SM Energy (SM).
06:13 EDTFEYECyberArk CEO: Lack of data breaches won't hurt company, Bloomberg says
CyberArk (CYBR) is distancing itself from FireEye (FEYE), saying that the lack of security breaches won't hurt the company, Bloomberg reports, citing comments from CyberArk CEO Udi Mokady. FireEye blamed a lull in cyber attacks for its downbeat quarterly earnings, the report says. "That is totally not the case in our world," Mokady said by phone from San Francisco last week. "It's not our business model -- our model is to put in private account security ahead of time, and we're seeing increased demand, increased awareness of that." Reference Link
06:06 EDTENDPEndo downgraded to Neutral from Buy at Mizuho
Subscribe for More Information
November 15, 2015
19:29 EDTMSFTMicrosoft delays, possibly kills tool to translate Android apps, Re/code says
Subscribe for More Information
November 13, 2015
16:00 EDTMSFTOptions Update; November 13, 2015
Subscribe for More Information
11:23 EDTENDPEndo management to meet with RBC Capital
Meeting to be held in Malvern, PA on November 16 hosted by RBC Capital.
10:49 EDTENDPMylan jumps, Perrigo plunges after hostile takeover bid fails
Shares of Mylan (MYL) jumped after the company's offer to acquire Perrigo (PRGO) failed. Perrigo shares fell after the news. WHAT'S NEW: Mylan's approximately $26B hostile takeover offer for Perrigo officially fell through Friday morning, ending a seven-month ordeal between the two companies. Mylan said that only about 40% of Perrigo's shares were tendered by the company's stockholders, falling short of the 50% required for an acquisition, forcing the offer to lapse after failing to meet its goal by the established deadline. In response to the news, Perrigo Chief Executive Officer Joseph Papa said he was "delighted" that his company's shareholders rejected the offer. "We have said all along that this offer from Mylan was a bad deal for our shareholders, as it significantly undervalued our durable business model and industry-leading future growth prospects," Papa said. Perrigo added that it will immediately commence its previously announced $2B share buyback and that it intends to complete $500M of the planned repurchase by the end of the year. WHAT'S NOTABLE: On July 27, Teva (TEVA) withdrew a takeover offer for Mylan amid Mylan's talks with Perrigo. The Israeli pharmaceutical company opted instead to purchase Allergan's (AGN) generics business. Commenting on its failure to buy Perrigo, Mylan Executive Chairman Robert Coury said in a statement that while the company viewed Perrigo as a "unique and exciting company," it was not required for the future success of the company. Coury said, "We are well-positioned to quickly execute on the next strategic, value-enhancing opportunities for our business, some of which we have already identified." STREET RESEARCH: Citi analyst Liav Abraham upgraded Mylan to Buy and raised her price target for shares to $59 from $52, saying that an overhang has been removed since the company's hostile attempt to buy Perrigo has fallen through. Abraham argued that a combination of the two companies would have been both destructive to both earnings and value for Mylan and that the failed bid will increase management's optionality to pursue other value-enhancing opportunities and enable investors to focus on the company's base business. In addition, RBC Capital Markets analyst Randall Stanicky confirmed a Sector Perform rating for both Mylan and Perrigo with price targets of $60 and $176, respectively. Stanicky said he expects Mylan's stock to gain 10%-15% towards $50 as a result of the news, while Perrigo will probably see a pull-back into the low $140s. The analyst added that the removal of the Mylan bid will drive initial weakness for Perrigo's shares but that the stock can settle close to its current levels. PRICE ACTION: In morning trading, Mylan rallied 12.5% to $48.60 and Perrigo fell 6.92% to $145.72. OTHERS TO WATCH: Teva shares trading in New York increased 0.26%, Allergan was up 0.66%, and Endo (ENDP), with which Reuters reported Perrigo held unsuccessful takeover talks, gained 5.56%.
10:00 EDTENDPEndo upgraded to Buy from Hold at Standpoint Research
Subscribe for More Information
09:58 EDTFEYEFireEye calls active on renewed takeover chatter
Subscribe for More Information
09:43 EDTFEYERumor: FireEye active on renewed takeover chatter
09:35 EDTMSFTActive equity options trading on open
Active equity options trading on open: AAPL CSCO FB BAC BABA MSFT NFLX INTC JCP AMZN C
06:27 EDTMSFTMicrosoft brings major updates to Xbox One, WSJ reports
Subscribe for More Information
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use